1. Home
  2. PPBI vs LIVN Comparison

PPBI vs LIVN Comparison

Compare PPBI & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBI
  • LIVN
  • Stock Information
  • Founded
  • PPBI 1983
  • LIVN 1987
  • Country
  • PPBI United States
  • LIVN United Kingdom
  • Employees
  • PPBI N/A
  • LIVN N/A
  • Industry
  • PPBI Major Banks
  • LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • PPBI Finance
  • LIVN Health Care
  • Exchange
  • PPBI Nasdaq
  • LIVN Nasdaq
  • Market Cap
  • PPBI N/A
  • LIVN 2.2B
  • IPO Year
  • PPBI 1997
  • LIVN 1993
  • Fundamental
  • Price
  • PPBI $21.70
  • LIVN $39.50
  • Analyst Decision
  • PPBI Buy
  • LIVN Buy
  • Analyst Count
  • PPBI 6
  • LIVN 7
  • Target Price
  • PPBI $27.00
  • LIVN $60.29
  • AVG Volume (30 Days)
  • PPBI 792.6K
  • LIVN 726.9K
  • Earning Date
  • PPBI 04-23-2025
  • LIVN 05-07-2025
  • Dividend Yield
  • PPBI 6.08%
  • LIVN N/A
  • EPS Growth
  • PPBI 438.96
  • LIVN 262.50
  • EPS
  • PPBI 1.65
  • LIVN 1.16
  • Revenue
  • PPBI $609,730,000.00
  • LIVN $1,253,437,000.00
  • Revenue This Year
  • PPBI N/A
  • LIVN $5.79
  • Revenue Next Year
  • PPBI $3.81
  • LIVN $5.35
  • P/E Ratio
  • PPBI $13.16
  • LIVN $34.14
  • Revenue Growth
  • PPBI 38.51
  • LIVN 8.66
  • 52 Week Low
  • PPBI $20.52
  • LIVN $36.85
  • 52 Week High
  • PPBI $30.28
  • LIVN $64.48
  • Technical
  • Relative Strength Index (RSI)
  • PPBI 40.19
  • LIVN 41.72
  • Support Level
  • PPBI $20.90
  • LIVN $38.53
  • Resistance Level
  • PPBI $22.10
  • LIVN $40.30
  • Average True Range (ATR)
  • PPBI 0.56
  • LIVN 1.02
  • MACD
  • PPBI 0.08
  • LIVN 0.22
  • Stochastic Oscillator
  • PPBI 46.78
  • LIVN 31.74

About LIVN LivaNova PLC

UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Share on Social Networks: